Bristol-Myers Squibb reported higher than expected quarterly earnings on Tuesday, helped by cost cuts and lower taxes. There were concerns over a possible delay in completing its marketing application for a high-profile cancer drug. BMY posted Q1 earnings of 56 cents per share, beating estimates of 43 cents a share, while revenue dipped to $3.81 billion, missing estimates of $3.89 billion. Bristol-Myers Squibb also announced the acquisition of iPierian for $175 million.

More from Video

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

Listen: Should You Buy Cisco Now?

Listen: Should You Buy Cisco Now?

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

It's Dumb to Think There Aren't Already Monopolies in Big Tech

It's Dumb to Think There Aren't Already Monopolies in Big Tech